MIM
HRTX icon

Monashee Investment Management’s Heron Therapeutics HRTX Stock Holding History

Monashee Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-130,000
Closed -$4.14M – 9
2018
Q1 		$3.59M Buy
+130,000
New +$2.95M 0.99% 32
2017
Q4 		– Hold
0
– – – 19

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Monashee Investment Management's HRTX Position: Q2 2018 in Review

Monashee Investment Management sold out of Heron Therapeutics (HRTX) in Q2 2018, closing a stake of 130,000 shares — an estimated $4.14M sold.

Monashee Investment Management first reported a position in HRTX in Q1 2018 and held it in 1 quarter. The position peaked at $3.59M in Q1 2018. 196 funds tracked by Wall St. Rank hold HRTX as of Q2 2018.

  • Monashee Investment Management reported no remaining Heron Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Monashee Investment Management sold 130,000 Heron Therapeutics shares in Q2 2018, an estimated $4.14M.
  • Monashee Investment Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 1 quarter.
  • Monashee Investment Management's Heron Therapeutics position peaked at $3.59M in Q1 2018.
  • 196 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2018.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.